RecruitingRecruiting
Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes
NCT07868666 · University of Minnesota
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes Pilot Study
About this study
Sodium-glucose co-transporter-2 inhibitors are FDA-approved medications for type 2 diabetes and have been shown to reduce kidney and cardiovascular risks in several patient populations. However, providers may be hesitant to prescribe SGLT2 inhibitors to patients who have recently experienced acute kidney injury because of concerns about kidney function changes after initiation.
This study is a pilot adaptive cluster randomized clinical trial conducted in participating M Health Fairview primary care clinics. Clinics will be randomized 1:1 to receive a clinical decision support intervention or continue usual care. The intervention consists of a message sent to the primary care provider or clinic pharmacist before a scheduled encounter with an eligible patient.
Eligible patients will be adults aged 30 to 75 years with type 2 diabetes, a history of acute kidney injury during a hospitalization with discharge within the prior year, and kidney function meeting study criteria. The study team will not provide SGLT2 inhibitors or direct treatment. All prescribing decisions, including whether to prescribe an SGLT2 inhibitor and which medication to use, will remain with the patient's usual provider and clinical care team.
The adaptive component applies only within the intervention arm. Patients in intervention clinics who attend a qualifying encounter but have no evidence of SGLT2i consideration may be randomized before a later qualifying encounter to receive either no further CDS messages or additional CDS messages.
The primary focus of this pilot study is feasibility. Outcomes will be collected from the electronic health record and the AHC/M Health Fairview data shelter. Feasibility outcomes include the number of eligible patients identified, CDS messages sent, providers or pharmacists receiving messages, patients with SGLT2i mentioned or prescribed, patients with follow-up kidney function data, and patients undergoing the second adaptive randomization step.
Eligibility criteria
Inclusion Criteria for Providers and Pharmacists:
* Assigned to work in a primary care specialty as a medical provider or assigned to work as a clinic pharmacist
* Assigned to work in one of the participating study clinics
Inclusion Criteria for Patients:
* Scheduled to be seen in a participating clinic with a physician or advanced practice provider in a primary care specialty or a clinic pharmacist
* Medical history of acute kidney injury during a hospitalization with discharge within 1 year before the scheduled appointment
* Medical history of type 2 diabetes mellitus (by billing code)
* Age 30 to 75 years at the date of study enrollment
* Available eGFR from labs more than 3 business days before the scheduled appointment and after AKI onset that is at least 30 mL/min/1.73 m²
* Either a serum creatinine lab measured after discharge from the hospitalization including the AKI, or the last serum creatinine lab during the hospitalization with AKI is less than 0.3 mg/dL above the patient's baseline serum creatinine concentration
Exclusion Criteria for Providers and Pharmacists:
* None
Exclusion Criteria for Patients:
* Opted out of research use of AHC/M Health Fairview data shelter data
* History of kidney transplantation as a recipient(by billing code)
* Pregnancy documented in AHC/M Health Fairview data shelter data (by billing code)
* SGLT2i allergy in the EHR allergy list
* Medical history of diabetic ketoacidosis, dementia, hospice care, or oncology care (by billing code and/or encounter)
* Medical history in the prior 1 year of indwelling Foley urinary catheter, cystitis, pyelonephritis, prostatitis, or urinary tract infection (by billing code)
* Serum creatinine rise of at least 0.3 mg/dL between the two most recent serum creatinine measurements
* Children
* Prisoners
Study design
Enrollment target: 250 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-11-02
Estimated completion: 2032-10-31
Last updated: 2026-11-04
Interventions
Other: Clinical Decision Support Message
Primary outcomes
- • Feasibility of Identifying Eligible Patients (From study start through completion of eligible patient identification, up to 4 years)
- • Feasibility of Clinical Decision Support Message Delivery (From study start through completion of the CDS intervention period, up to 4 years)
- • SGLT2i Consideration After Clinical Decision Support (At the first qualifying primary care encounter)
Sponsor
University of Minnesota · other
With: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contacts & investigators
ContactDaniel P. Murphy · contact · murph670@umn.edu · 612-624-9444
InvestigatorDaniel Murphy · principal_investigator, University of Minnesota
All locations (1)
University of MinnesotaRecruiting
Minneapolis, Minnesota, United States